Advertisement

Pharmaceutical Research

, Volume 31, Issue 1, pp 216–227 | Cite as

In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice

  • Vasco Filipe
  • Ivo Que
  • John F. Carpenter
  • Clemens Löwik
  • Wim JiskootEmail author
Research Paper

ABSTRACT

Purpose

To monitor the biodistribution of IgG1 aggregates upon subcutaneous (SC) and intravenous (IV) administration in mice and measure their propensity to stimulate an early immune response.

Methods

A human mAb (IgG1) was fluorescently labeled, aggregated by agitation stress and injected in SKH1 mice through SC and IV routes. The biodistribution of monomeric and aggregated formulations was monitored over 47 days by fluorescence imaging and the early immune response was measured by quantifying the level of relevant cytokines in serum using a Bio-plex assay.

Results

The aggregates remained at the SC injection site for a longer time than monomers but after entry into the systemic circulation disappeared faster than monomers. Upon IV administration, both monomers and aggregates spread rapidly throughout the circulation, and a strong accumulation in the liver was observed for both species. Subsequent removal from the circulation was faster for aggregates than monomers. No accumulation in lymph nodes was observed after SC or IV administration. Administration of monomers and aggregates induced similar cytokine levels, but SC injection resulted in higher cytokine levels than IV administration.

Conclusion

These results show differences in biodistribution and residence time between IgG1 aggregates and monomers. The long residence time of aggregates at the SC injection site, in conjunction with elevated cytokine levels, may contribute to an enhanced immunogenicity risk of SC injected aggregates compared to that of monomers.

KEY WORDS

biodistribution fluorescence imaging innate immune response intravenous monoclonal antibodies protein aggregates subcutaneous 

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

The authors acknowledge Els van Beelen for her help with the Bio-Plex assay.

Supplementary material

11095_2013_1154_Fig7_ESM.jpg (46 kb)
Appendix A

Representative fluorescence images over time of monomeric and aggregated 800CW-IgG1 upon SC injection in SKH1 mice. Five mice per group were imaged and used for fluorescence quantification purposes. Dorsal and ventral images of the same mouse were obtained throughout a time period of 47 days after injection. The fluorescence threshold of the first time points (upper panel) was optimized to not over-expose the first time point (Settings 1). The fluorescence threshold of the last time points (lower panel) was optimized to show the maximum fluorescence possible before auto-fluorescence was reached (Settings 2). (JPEG 46 kb)

11095_2013_1154_MOESM1_ESM.tif (6 mb)
High resolution image (TIFF 6112 kb)
11095_2013_1154_Fig8_ESM.jpg (56 kb)
Appendix B

Representative fluorescence images over time of monomeric and aggregated 800CW-IgG1 upon IV injection in SKH1 mice. Five mice per group were imaged and used for fluorescence quantification purposes. Dorsal and ventral images of the same mouse were obtained throughout a time period of 47 days after injection. The fluorescence threshold of the first time points (upper panel) was optimized to not over-expose the first time point (Settings 1). The fluorescence threshold of the last time points (lower panel) was optimized to show the maximum fluorescence possible before auto-fluorescence was reached (Settings 2). (JPEG 56 kb)

11095_2013_1154_MOESM2_ESM.tif (6 mb)
High resolution image (TIFF 6115 kb)
11095_2013_1154_Fig9_ESM.jpg (52 kb)
Appendix C

Fluorescence images over time of non-reactive free 800CW (green) and RD680 (red) dyes upon SC and IV injection in SKH1 mice. The upper panel corresponds to SC injections and the lower panel to an IV injection. One mouse per group was imaged. Dorsal and ventral images were obtained throughout a time period of 3 days after injection. (JPEG 51 kb)

11095_2013_1154_MOESM3_ESM.tif (13.2 mb)
High resolution image (TIFF 13507 kb)

REFERENCES

  1. 1.
    Lawrence S. Pipelines turn to biotech. Nat Biotechnol. 2007;25:1342.PubMedCrossRefGoogle Scholar
  2. 2.
    Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14:296–302.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720–40. discussion 1719.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501–507.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Gamble CN. The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int Arch allergy Appl immunol. 1966;30:446–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997;14:1472–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs. 2012;4:740–75.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res. 2011;28:2393–402.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95:1084–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Ferraiolo BL, Mohler MA, Gloff CA. Protein pharmacokinetics and metabolism. New York: Plenum Press; 1992.CrossRefGoogle Scholar
  11. 11.
    Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, et al. Development of a subcutaneous formulation for trastuzumab—nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung. 2012;62:401–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.PubMedCrossRefGoogle Scholar
  13. 13.
    Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.PubMedCrossRefGoogle Scholar
  14. 14.
    Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007;67:759–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos. 2012;40:952–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89:297–310.PubMedCrossRefGoogle Scholar
  17. 17.
    Baumann A. Early development of therapeutic biologics–pharmacokinetics. Curr Drug Metab. 2006;7:15–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93:2184–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507.PubMedCrossRefGoogle Scholar
  20. 20.
    Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3:422–30.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885–900.PubMedCrossRefGoogle Scholar
  22. 22.
    Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci. 2010;99:1028–45.PubMedGoogle Scholar
  23. 23.
    Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B. 2010;98:77–94.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Hillman EM, Amoozegar CB, Wang T, McCaslin AF, Bouchard MB, Mansfield J, et al. In vivo optical imaging and dynamic contrast methods for biomedical research. Philos Transact A Math Phys Eng Sci. 2011;369:4620–43.CrossRefGoogle Scholar
  25. 25.
    Barnard JG, Singh S, Randolph TW, Carpenter JF. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci. 2011;100:492–503.PubMedCrossRefGoogle Scholar
  26. 26.
    Philo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol. 2009;10:359–72.PubMedCrossRefGoogle Scholar
  27. 27.
    Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287:25266–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall’acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol. 2009;46:1750–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58.PubMedCrossRefGoogle Scholar
  31. 31.
    Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013;41:248–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285:4826–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98:1201–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Robinson WL. Some points of the mechanism of filtration by the spleen. Am J Pathol. 1928;4:309–20. 303.PubMedGoogle Scholar
  35. 35.
    Tasciotti E, Godin B, Martinez JO, Chiappini C, Bhavane R, Liu X, et al. Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging. 2011;10:56–68.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Bogers WM, Stad RK, Janssen DJ, van Rooijen N, van Es LA, Daha MR. Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin Exp Immunol. 1991;86:328–33.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Helmy KY, Katschke Jr KJ, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124:915–27.PubMedCrossRefGoogle Scholar
  38. 38.
    Hawe A, Friess W, Sutter M, Jiskoot W. Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem. 2008;378:115–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99:3302–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869–78.PubMedCrossRefGoogle Scholar
  41. 41.
    Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897–903.PubMedCrossRefGoogle Scholar
  42. 42.
    Kijanka G, Jiskoot W, Schellekens H, Brinks V. Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res. 2013;30:1553–60.Google Scholar
  43. 43.
    McLennan DN, Porter CJ, Edwards GA, Heatherington AC, Martin SW, Charman SA. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm Res. 2006;23:2060–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Charman SA, McLennan DN, Edwards GA, Porter CJ. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res. 2001;18:1620–6.PubMedCrossRefGoogle Scholar
  45. 45.
    McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, Charman SA. Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther. 2005;313:345–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Wu F, Bhansali SG, Law WC, Bergey EJ, Prasad PN, Morris ME. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012;29:1843–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012;29:490–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, Charman SA. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metabol Dis Biol Fate Chem. 2007;35:2211–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Vasco Filipe
    • 1
  • Ivo Que
    • 2
  • John F. Carpenter
    • 3
  • Clemens Löwik
    • 2
  • Wim Jiskoot
    • 1
    Email author
  1. 1.Division of Drug Delivery Technology Leiden Academic Center for Drug ResearchLeiden UniversityLeidenThe Netherlands
  2. 2.Department of RadiologyLeiden University Medical CentreLeidenThe Netherlands
  3. 3.Department of Pharmaceutical SciencesUniversity of Colorado DenverAuroraUSA

Personalised recommendations